DK0991628T3 - Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaser - Google Patents
Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaserInfo
- Publication number
- DK0991628T3 DK0991628T3 DK98925022T DK98925022T DK0991628T3 DK 0991628 T3 DK0991628 T3 DK 0991628T3 DK 98925022 T DK98925022 T DK 98925022T DK 98925022 T DK98925022 T DK 98925022T DK 0991628 T3 DK0991628 T3 DK 0991628T3
- Authority
- DK
- Denmark
- Prior art keywords
- quinoline
- growth factor
- derived growth
- inhibit platelet
- p561ck
- Prior art date
Links
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 title abstract 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 title abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 230000006052 T cell proliferation Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86445597A | 1997-05-28 | 1997-05-28 | |
| US97261497A | 1997-11-18 | 1997-11-18 | |
| PCT/US1998/010999 WO1998054156A1 (en) | 1997-05-28 | 1998-05-28 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0991628T3 true DK0991628T3 (da) | 2005-05-17 |
Family
ID=27127839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98925022T DK0991628T3 (da) | 1997-05-28 | 1998-05-28 | Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaser |
Country Status (25)
| Country | Link |
|---|---|
| EP (3) | EP1001946B1 (enExample) |
| JP (3) | JP2002500675A (enExample) |
| KR (2) | KR100440756B1 (enExample) |
| CN (3) | CN1280572A (enExample) |
| AP (3) | AP1554A (enExample) |
| AT (3) | ATE493389T1 (enExample) |
| AU (3) | AU742739B2 (enExample) |
| BG (3) | BG64444B1 (enExample) |
| BR (3) | BR9809501A (enExample) |
| CA (3) | CA2291750A1 (enExample) |
| CZ (3) | CZ298521B6 (enExample) |
| DE (3) | DE69828607T2 (enExample) |
| DK (1) | DK0991628T3 (enExample) |
| EA (4) | EA004103B1 (enExample) |
| ES (1) | ES2235331T3 (enExample) |
| HU (2) | HUP0002084A3 (enExample) |
| IL (3) | IL133009A0 (enExample) |
| NO (3) | NO323720B1 (enExample) |
| OA (3) | OA11264A (enExample) |
| PL (3) | PL194980B1 (enExample) |
| PT (1) | PT991628E (enExample) |
| SI (1) | SI0991628T1 (enExample) |
| SK (4) | SK158099A3 (enExample) |
| UA (1) | UA57790C2 (enExample) |
| WO (3) | WO1998054158A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159978A (en) * | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| IL133009A0 (en) * | 1997-05-28 | 2001-03-19 | Aventis Pharm Prod Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| EP1309596B1 (en) | 2000-08-11 | 2008-02-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| ATE398108T1 (de) | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
| DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| HRP20060100T3 (en) | 2003-07-22 | 2007-03-31 | Arena Pharmaceuticals Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| CN1930128A (zh) | 2004-01-16 | 2007-03-14 | 惠氏公司 | 受体酪氨酸激酶抑制剂的喹啉中间体及其合成 |
| JP2010526823A (ja) | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体 |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| EP2241557A1 (de) | 2009-04-02 | 2010-10-20 | Æterna Zentaris GmbH | Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen |
| CN102596932A (zh) | 2009-09-04 | 2012-07-18 | 拜耳医药股份有限公司 | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| CN101823998B (zh) * | 2010-05-05 | 2015-03-25 | 江苏利田科技股份有限公司 | 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺 |
| BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| JP5990187B2 (ja) | 2010-12-16 | 2016-09-07 | ニヴァリス・セラピューティクス・インコーポレーテッド | Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014159690A1 (en) | 2013-03-12 | 2014-10-02 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| PT3008062T (pt) | 2013-06-11 | 2017-06-07 | Bayer Pharma AG | Derivados de profármaco de triazolopiridinas substituídas |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| WO2017044766A1 (en) | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Solid forms of an s-nitrosoglutathione reductase inhibitor |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| KR102691777B1 (ko) | 2015-09-23 | 2024-08-02 | 얀센 파마슈티카 엔브이 | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| WO2018064092A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU583793B2 (en) * | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| US4888427A (en) * | 1987-04-07 | 1989-12-19 | University Of Florida | Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain |
| GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU658646B2 (en) * | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| KR100224135B1 (ko) * | 1993-01-28 | 1999-10-15 | 다께다 구니오 | 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도 |
| DE4426373A1 (de) * | 1994-07-26 | 1996-02-01 | Bayer Ag | 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung |
| ATE338754T1 (de) * | 1996-07-19 | 2006-09-15 | Takeda Pharmaceutical | Heterocyclische verbindungen, ihre herstellung und verwendung |
| AU5574798A (en) * | 1997-01-21 | 1998-08-07 | Nissan Chemical Industries Ltd. | Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines |
| IL133009A0 (en) * | 1997-05-28 | 2001-03-19 | Aventis Pharm Prod Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
-
1998
- 1998-05-28 IL IL13300998A patent/IL133009A0/xx not_active IP Right Cessation
- 1998-05-28 SK SK1580-99A patent/SK158099A3/sk unknown
- 1998-05-28 EA EA199901090A patent/EA004103B1/ru not_active IP Right Cessation
- 1998-05-28 DK DK98925022T patent/DK0991628T3/da active
- 1998-05-28 EP EP98926129A patent/EP1001946B1/en not_active Expired - Lifetime
- 1998-05-28 WO PCT/US1998/011036 patent/WO1998054158A1/en not_active Ceased
- 1998-05-28 HU HU0002084A patent/HUP0002084A3/hu unknown
- 1998-05-28 IL IL13300798A patent/IL133007A/xx not_active IP Right Cessation
- 1998-05-28 KR KR10-1999-7011036A patent/KR100440756B1/ko not_active Expired - Fee Related
- 1998-05-28 JP JP50096599A patent/JP2002500675A/ja not_active Ceased
- 1998-05-28 BR BR9809501-3A patent/BR9809501A/pt not_active Application Discontinuation
- 1998-05-28 UA UA99127137A patent/UA57790C2/uk unknown
- 1998-05-28 EA EA199901086A patent/EA002600B1/ru not_active IP Right Cessation
- 1998-05-28 SI SI9830741T patent/SI0991628T1/ unknown
- 1998-05-28 KR KR10-1999-7010972A patent/KR100425638B1/ko not_active Expired - Fee Related
- 1998-05-28 CA CA002291750A patent/CA2291750A1/en not_active Abandoned
- 1998-05-28 BR BR9809515-3A patent/BR9809515A/pt not_active Application Discontinuation
- 1998-05-28 CA CA002291774A patent/CA2291774A1/en not_active Abandoned
- 1998-05-28 DE DE69828607T patent/DE69828607T2/de not_active Expired - Lifetime
- 1998-05-28 AT AT98926129T patent/ATE493389T1/de not_active IP Right Cessation
- 1998-05-28 AP APAP/P/1999/001710A patent/AP1554A/en active
- 1998-05-28 PL PL337086A patent/PL194980B1/pl unknown
- 1998-05-28 JP JP50098799A patent/JP2002500676A/ja not_active Ceased
- 1998-05-28 AT AT98925041T patent/ATE500233T1/de not_active IP Right Cessation
- 1998-05-28 JP JP50096499A patent/JP2002513417A/ja not_active Ceased
- 1998-05-28 PL PL98337087A patent/PL195552B1/pl not_active IP Right Cessation
- 1998-05-28 AU AU78037/98A patent/AU742739B2/en not_active Ceased
- 1998-05-28 CN CN98806454A patent/CN1280572A/zh active Pending
- 1998-05-28 AT AT98925022T patent/ATE286886T1/de not_active IP Right Cessation
- 1998-05-28 AP APAP/P/1999/001711A patent/AP1362A/en active
- 1998-05-28 CZ CZ0415899A patent/CZ298521B6/cs not_active IP Right Cessation
- 1998-05-28 HU HU0004807A patent/HUP0004807A3/hu unknown
- 1998-05-28 IL IL13300898A patent/IL133008A0/xx not_active IP Right Cessation
- 1998-05-28 EP EP98925041A patent/EP1001945B1/en not_active Expired - Lifetime
- 1998-05-28 CA CA002291728A patent/CA2291728A1/en not_active Abandoned
- 1998-05-28 ES ES98925022T patent/ES2235331T3/es not_active Expired - Lifetime
- 1998-05-28 PL PL98337084A patent/PL194670B1/pl not_active IP Right Cessation
- 1998-05-28 CZ CZ0418099A patent/CZ296845B6/cs not_active IP Right Cessation
- 1998-05-28 DE DE69842151T patent/DE69842151D1/de not_active Expired - Lifetime
- 1998-05-28 SK SK1581-99A patent/SK158199A3/sk unknown
- 1998-05-28 EP EP98925022A patent/EP0991628B1/en not_active Expired - Lifetime
- 1998-05-28 WO PCT/US1998/010999 patent/WO1998054156A1/en not_active Ceased
- 1998-05-28 AU AU77079/98A patent/AU751188C/en not_active Ceased
- 1998-05-28 DE DE69842077T patent/DE69842077D1/de not_active Expired - Lifetime
- 1998-05-28 CN CNB98806538XA patent/CN1140516C/zh not_active Expired - Fee Related
- 1998-05-28 AU AU77062/98A patent/AU747026B2/en not_active Ceased
- 1998-05-28 AP APAP/P/1999/001709A patent/AP1444A/en active
- 1998-05-28 WO PCT/US1998/011000 patent/WO1998054157A1/en not_active Ceased
- 1998-05-28 PT PT98925022T patent/PT991628E/pt unknown
- 1998-05-28 CN CN98806430A patent/CN1261353A/zh active Pending
- 1998-05-28 EA EA199901092A patent/EA008136B1/ru not_active IP Right Cessation
- 1998-05-28 BR BR9809172-7A patent/BR9809172A/pt not_active Application Discontinuation
- 1998-05-28 SK SK1579-99A patent/SK157999A3/sk unknown
- 1998-05-28 SK SK114-2005A patent/SK286084B6/sk not_active IP Right Cessation
- 1998-05-28 CZ CZ0417999A patent/CZ298490B6/cs not_active IP Right Cessation
-
1999
- 1999-11-23 EA EA200100575A patent/EA007807B1/ru not_active IP Right Cessation
- 1999-11-26 NO NO19995818A patent/NO323720B1/no unknown
- 1999-11-26 NO NO19995819A patent/NO323721B1/no unknown
- 1999-11-26 NO NO19995817A patent/NO316377B1/no unknown
- 1999-11-29 OA OA9900260A patent/OA11264A/en unknown
- 1999-11-29 OA OA9900262A patent/OA11222A/en unknown
- 1999-11-29 OA OA9900261A patent/OA11221A/en unknown
- 1999-12-08 BG BG103963A patent/BG64444B1/bg unknown
- 1999-12-08 BG BG103965A patent/BG64419B1/bg unknown
- 1999-12-14 BG BG104006A patent/BG64445B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0991628T3 (da) | Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaser | |
| NZ512096A (en) | Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors | |
| BG105629A (en) | Quinoline and quinoxaline compounds | |
| ATE281451T1 (de) | Imidazolderivate und deren verwendung als raf kinase inhibitoren | |
| EA200100576A1 (ru) | Хинолиновые и хиноксалиновые соединения, как ингибиторы тфр-р и/или lck тирозинкиназы | |
| TR200200928T2 (tr) | 2-pirazolin-5-on terkipleri | |
| ATE230394T1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
| AP1486A (en) | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use. | |
| BRPI0409173A (pt) | compostos e composições como inibidores de proteìna quinase | |
| DE60029138D1 (de) | Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase | |
| ATE341545T1 (de) | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase | |
| BG105112A (bg) | Средство с антидепресивно действие | |
| PT909315E (pt) | Cck-2, um receptor da tirosina cinase | |
| ES2249309T3 (es) | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. | |
| ATE269340T1 (de) | Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |